Tumour suppressor gene TP53 mutations in atypical vascular lesions of breast skin following radiotherapy

Histopathology

Volumn 58, Issue 3, 2011, Pages 455-466

  Santi, Raffaella ^a   Cetica, Valentina ^a   Franchi, Alessandro ^a   Pepi, Monica ^a   Cesinaro, Anna M ^b   Miracco, Clelia ^c   Paglierani, Milena ^a   De Giorgi, Vincenzo ^a   Delfino, Chiara ^a   Difonzo, Elisa M ^a   Pimpinelli, Nicola ^a   Bianchi, Simonetta ^a   Sardi, Iacopo ^a   Santucci, Marco ^a   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Angiosarcoma; Atypical vascular lesions; Breast skin; Radiation therapy; TP53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; BREAST; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CODON; CONSERVATIVE TREATMENT; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; SKIN; TUMOR SUPPRESSOR GENE; VASCULAR LESION;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, P53; HEMANGIOSARCOMA; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, RADIATION-INDUCED; SKIN; VASCULAR DISEASES;

EID: 79952081159     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03770.x     Document Type: Article

References (35)

1. Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am. J. Clin. Pathol. 1994; 102; 757-763.
2. Diaz-Cascajo C, Borghi S, Weyers W, Retzlaff H, Requena L, Metze D. Benign lymphangiomatous papules of the skin following radiotherapy: a report of five new cases and review of the literature. Histopathology 1999; 35; 319-327.
3. Brenn T, Fletcher CD. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am. J. Surg. Pathol. 2005; 29; 983-996.
4. Mattoch IW, Robbins JB, Kempson RL, Kohler S. Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases. J. Am. Acad. Dermatol. 2007; 57; 126-133.
5. Patton KT, Deyrup AT, Weiss SW. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am. J. Surg. Pathol. 2008; 32; 943-950.
6. Di Tommaso L, Fabbri A. Cutaneous angiosarcoma arising after radiotherapy treatment of a breast carcinoma. Description of a case and review of the literature. Pathologica 2003; 95; 196-202.
7. Uchin JM, Billings SD. Radiotherapy-associated atypical vascular lesions of the breast. J. Cutan. Pathol. 2009; 36; 87-88.
8. Requena L, Kutzner H, Mentzel T, Durán R, Rodríguez-Peralto JL. Benign vascular proliferations in irradiated skin. Am. J. Surg. Pathol. 2002; 26; 328-337.
9. Rosso R, Gianelli U, Carnevali L. Acquired progressive lymphangioma of the skin following radiotherapy for breast carcinoma. J. Cutan. Pathol. 1995; 22; 164-167.
10. Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356; 215-221.
11. Hollstein M, Marion MJ, Lehman T et al. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994; 15; 1-3.
12. Soini Y, Welsh JA, Ishak KG, Bennett WP. p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis 1995; 16; 2879-2881.
13. Naka N, Tomita Y, Nakanishi H et al. Mutations of p53 tumor-suppressor gene in angiosarcoma. Int. J. Cancer 1997; 71; 952-955.
14. Kieser A, Weich HA, Brandner G, Marmé D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9; 963-969.
15. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc. Natl. Acad. Sci. USA 1989; 86; 7311-7315.
16. Hashimoto M, Ohsawa M, Ohnishi A et al. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab. Invest. 1995; 73; 859-863.
17. Coombs NJ, Gough AC, Primrose JN. Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res. 1999; 27; e12.
18. Whibley C, Pharoah PD, Hollstein M. p53 polymorphism: cancer implications. Nat. Rev. Cancer 2009; 9; 95-107.
19. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265; 346-355.
20. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393; 229-234.
21. Sourvinos G, Rizos E, Spandidos DA. p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol. 2001; 37; 572-578.
22. Cortezzi SS, Provazzi PJ, Sobrinho JS et al. Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet. Cytogenet. 2004; 150; 44-49.
23. Siddique MM, Balram C, Fiszer-Maliszewska L et al. Evidence for selective expression of the p53 codon 72 polymorphism implications in cancer development. Cancer Epidemiol. Biomarkers Prev. 2005; 14; 2245-2252.
24. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005; 26; 1770-1773.
25. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007; 26; 1317-1323.
26. Marin MC, Jost CA, Brooks LA et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000; 25; 47-54.
27. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002; 179; 175-183.
28. Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int. J. Oncol. 2002; 21; 1151-1154.
29. Toyama T, Zhang Z, Nishio M et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007; 9; R34.
30. Klug SJ, Ressing M, Koenig J et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009; 10; 772-784.
31. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003; 18; 377-385.
32. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum. Pathol. 1999; 30; 1221-1225.
33. Zietz C, Rössle M, Haas C et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 1998; 153; 1425-1433.
34. Amo Y, Masuzawa M, Hamada Y, Katsuoka K. Expression of vascular endothelial growth factor in a human hemangiosarcoma cell line (ISO-HAS). Arch. Dermatol. Res. 2001; 293; 296-301.
35. Gengler C, Coindre JM, Leroux A et al. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group. Cancer 2007; 109; 1584-1598.